Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00493467
Status:
COMPLETED
Last Update Posted:
2022-09-15
First Post:
2007-06-27
Brief Title:
Zevalin Ibritumomab Tiuxetan for Early Stage Indolent Lymphomas
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Organization Data
Organization:
MD Anderson Cancer Center
Class:
OTHER
Study ID:
2005-0512
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MD Anderson Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| CTI BioPharma | INDUSTRY |
| Biogen | INDUSTRY |